Muñoz-Jimenez M, Zaarkti A, García-Arnes JA, et al. - In patients with Alzheimer’s disease (AD), mild cognitive impairment (MCI), or subjective cognitive complaints (SCCs, this systematic review was performed to evaluate the effectiveness of antidiabetic drugs. Researchers carried out to search electronic databases PubMed/MEDLINE, EMBASE, and Scopus seeking clinical trials assessing the impact of antidiabetic drugs on cognition in patients with AD, MCI, or SCCs. A total of 23 articles were included. The evidence suggested that intranasal insulin, pioglitazone, metformin, and liraglutide are promising drugs that could be beneficial in the treatment of AD. In most studies, verbal memory improved with intranasal regular insulin use, particularly in apoE4− patients, but results in other cognitive domains were not clear. Cognition improved after 2 months of treatment with detemir, but it did not after 4 months. Cognition improved in diabetic patients with AD or MCI using pioglitazone in three clinical trials, but it not in two other studies. Promising results were seen with metformin and liraglutide showed, but further research is needed. Nearly all drugs tested were shown to modulate AD biomarkers and imaging. At this time, no specific antidiabetic drug can recently be recommended to treat AD.